Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy

Theoretical Biology and Medical Modelling

Volumn 10, Issue 1, 2013, Pages

  Ravanbakhsh, Siamak ^a,b   Gajewski, Melissa ^a   Greiner, Russell ^a,b   Tuszynski, Jack A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Alberta Machine Intelligence Institute   (Canada)

Author keywords

Bioinformatics; Cancer; Drug design; Optimization; Side effects; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; TUBULIN;

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; NEOPLASM; NEOPLASMS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; TUBULIN;

EID: 84876782337     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-10-29     Document Type: Article

References (40)

1. Microtubules as a target for anticancer drugs. Jordan M, Wilson L, Nat Rev Canc 2004 4 253 265 10.1038/nrc1317
2. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Rowinsky E, Burke P, Karp J, Tucker R, Ettinger D, Donehower R, Canc Res 1989 49 4640 4647
3. The tubulin fraternity: alpha to eta. Dutcher S, Curr Opin Cell Biol 2001 13 49 54 10.1016/S0955-0674(00)00173-3 11163133
4. The mechanism of microtubule associated cytoplasmic transport. Isolation and preliminary characterisation of a microtubule transport system. Hyams J, Stebbings H, Cell Tissue Res 1979 196 103 116 570458
5. The evolution of cellular movement in eukaryotes: the role of microfilaments and microtubules. Pichichero M, Avers C, Subcell Biochem 1973 2 97 105 10.1007/BF01738683 4593908
6. Dustin P, Microtubules Berlin: Springer 2 1984
7. Comparative modelling of human β tubulin isotypes and implications for drug binding. Huzil J, Ludueña R, Tuszynski J, Nanotechnology 2006 17 90 S100 10.1088/0957-4484/17/4/014 21727360
8. Dynamic instability of microtubule growth. Mitchison T, Kirschner M, Nature 1984 312 237 242 10.1038/312237a0 6504138
9. Multiple forms of tubulin: different gene products and covalent modifications. Ludueña R, Int Rev Cytol 1998 178 207 275 9348671
10. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Leandro-García L, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, Letón R, Cascón A, Robledo M, Rodríguez-Antona C, Cytoskeleton (Hoboken) 2010 67 214 223 10.1002/cm.20436
11. Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues. Roach M, Boucher V, Walss C, Ravdin P, Ludueña R, Cell Motil Cytoskeleton 1998 39 273 285 10.1002/(SICI)1097- 0169(1998)39:4<273::AID-CM3>3.0.CO;2-4 9580378
12. Beta-tubulin epitope expression in normal and malignant epithelial cells. Scott C, Walker C, Neal D, Harper C, Bloodgood R, Somers K, Mills S, Rebhun L, Levine P, Arch Otolaryngol Head Neck Surg 1990 116 583 589 10.1001/archotol. 1990.01870050083012 1691648
13. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Rosell R, Scagliotti G, Danenberg K, Lord R, Bepler G, Novello S, Cooc J, Crinò L, Sánchez J, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D, Stephens C, Oncogene 2003 22 3548 3553 10.1038/sj.onc.1206419 12789263
14. Class V β-tubulin alters dynamic instability and stimulates microtubule detachment from centrosomes. Bhattacharya R, Yang H, Cabral F, Mol Biol Cell 2011 22 1025 1034 10.1091/mbc.E10-10-0822 21289088
15. Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration. Ganguly A, Yang H, Cabral F, Oncotarget 2011 2 368 377 21576762
16. Refined structure of alpha beta-tubulin at 3.5 A resolution. Löwe J, Li H, Downing K, Nogales E, J Mol Biol 2001 313 1045 1057 10.1006/jmbi.2001. 5077 11700061
17. Gajewski M, Host/Guest Chemistry: From Rings and Metals to Proteins and Drugs. PhD thesis Edmonton, Canada: University of Alberta, Department of Chemistry 2011
18. Computational design and biological testing of highly cytotoxic colchicine ring A modifications. Huzil J, Winter P, Johnson L, Weis A, Bakos T, Banerjee A, Luduena R, Damaraju S, Tuszynski J, Chem Biol Drug Des 2010 75 541 550 10.1111/j.1747-0285.2010.00970.x 20408852
19. Interaction of nocodazole with tubulin isotypes. Xu K, Schwarz PM, Ludueña RF, Drug Dev Res 2002 55 91 96 10.1002/ddr.10023
20. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. Banerjee A, Luduena RF, J Biol Chem 1992 267 13335 13339 1618835
21. Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives. Tseng CY, Mane J, Winter P, Johnson L, Huzil T, Izbicka E, Luduena R, Tuszynski J, Mol Canc 2010 9 131 10.1186/1476-4598-9-131
22. Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells. Lobert S, Jefferson B, Morris K, Cytoskeleton 2011 68 355 362 10.1002/cm.20517 21634028
23. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Hiser L, Aggarwal A, Young R, Frankfurter A, Spano A, Correia J, Lobert S, Cell Motil Cytoskeleton 2006 6 41 52
24. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Löbenberg R, Roac WH, Int J Pharm 2006 319 155 161 10.1016/j.ijpharm.2006. 03.052 16713150
25. Cassidy J, Oxford handbook of oncology Oxford: Oxford University Press 2002
26. Bertsimas D, Tsitsiklis J, Introduction to linear optimization Belmont, MA: Athena Scientific 1997
27. Luenberger D, Linear and nonlinear programming Reading, MA: Addison-Wesley 2 1984
28. Papadimitriou C, Steiglitz K, Combinatorial optimization: algorithms and complexity Mineola, NY: Dover Publications 1998
29. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Derry W, Wilson L, Khan I, Luduena R, Jordan M, Biochemistry 1998 36 3554 3562
30. Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Khan I, Ludueña R, Invest New Drugs 2003 21 3 13 10.1023/A:1022946305242 12795525
31. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. Kavallaris M, Kuo D, Burkhart C, Regl D, Norris M, Haber M, Horwitz S, J Clin Invest 1997 100 1282 1293 10.1172/JCI119642 9276747
32. Bertsekas D, Nonlinear programming Belmont, MA: Athena Scientific 2 1999
33. Geometric programming duals of channel capacity and rate distortion. Chiang M, Boyd S, IEEE Trans Inf Theory 2004 50 245 258 10.1109/TIT.2003.822581
34. Kullback S, Information theory and statistics Mineola, NY: Dover Publications 1997
35. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti F, Ferrandina G, Scambia G, Clin Canc Res 2005 11 298 305
36. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G, Canc Res 2005 65 2397 2405 10.1158/0008-5472.CAN-04-3065
37. Non-toxic melanoma therapy by a novel tubulin-binding agent. Aneja R, Asress S, Dhiman N, Awasthi A, Rida P, Arora S, Zhou J, Glass J, Joshi H, Int J Canc 2010 126 256 265 10.1002/ijc.24765
38. Microtubule-binding agents: a dynamic field of cancer therapeutics. Dumontet C, Jordan M, Nat Rev Drug Discov 2010 9 790 803 10.1038/nrd3253 20885410
39. Mitotic Centromere-associated Kinesin (MCAK) Mediates Paclitaxel Resistance. Ganguly A, Yang H, Pedroza M, Bhattacharya R, Cabral F, J Biol Chem 2010 285 32242 32250 10.1074/jbc.M110.160820 20696757
40. New insights into mechanisms of resistance to microtubule inhibitors. Ganguly A, Cabral F, Biochim Biophys Acta 1816 2011 164 171